Valion Bio names Dean Zikria interim CEO
VBIO•Board leadership changes
The board appointed Thomas Jensen chair, also naming him chair of the compensation committee, replacing departing director Sheryle Bolton.
Jared Malbin took over as audit committee chair.
Valion Bio appoints interim CEO
Valion Bio named board member Dean Zikria interim CEO to steer strategy, including Entolimod development and partnership efforts.
Zikria’s background at Pfizer
Zikria previously held strategy and business development roles at Pfizer’s USD 7 billion US cardiovascular business.
